Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

Final results of the OCEAN(a)-DOSE trial – published in the New England Journal of Medicine – showed that the small, interfering RNA (siRNA) drug reduced Lp(a) levels compared to placebo at ...

A new study led by Profs. Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences ...

As a molecule, siRNA goes against just about every rule in the traditional drug discovery book. Compared with small molecules, siRNA is large, covered in negative charges, and doesn’t easily cro ...

The GalNAc technology will be used in the first two agreements, combining it with two small ... siRNA therapies, and known for its effectiveness in reaching liver cells. Several US Food and Drug ...

In a recent publication in Cell Reports Medicine, a collaborative research team led by Chen-Yu Zhang and Huan Wang at Nanjing ...

Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases- Lead target ...

Multidrug-resistant bacteria pose a major threat to human health. Manipulation of bacterial genes at the transcriptional level is a potential strategy to fight antibiotic-resistant bacterial ...

Materials & Methods: The NDS consisted of cationic liposomes (carrier, 100–140 nm), doxorubicin (DOX, anticancer drug), siRNA targeted to MRP1 and BCL2 mRNA (suppressors of pump and nonpump ...